WNT-SIGNALING PATHWAY IN THE BONE TISSUE STUDIES

1. Nusse R, Varmus H. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 1982, 31, 99-109

2. Nüsslein-Volhard C, Wieschaus E (October 1980). «Mutations affecting segment number and polarity in Drosophila». Nature 287 (5785): 795-801. DOI:10.1038/287795a0. PMID 6776413.

3. Holstein TW. The evolution of the Wnt pathway. Cold Spring Harb Perspect Biol 2012, 4: a007922

4. Clevers H, Nusse R.: Wnt/β-Catenin signaling and disease. Cell, 2012, 149, 1192-1205

5. Willert K, Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol, 2012, 4:a007864

6. Wang Y, Li Y, Paulson C, Shao J-Z, Zhang X, Wu M, Chen.: Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci, 2014, 19, 379-407

7. Гребенникова ТА, Белая ЖЕ, Рожинская ЛЯ, Мельниченко ГА, Дедов ИИ: Эпигенетические аспекты остеопороза. Вестник Российской Академии Медицинских Наук, 2015, Том 70, №5, стр. 541-548

8. Yavropoulou MP, Xygonakis C, Lolou M, Karadimou F, Yovos JG.: The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis. Hormones, 2014, 13, 476-487

9. Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II.: Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. J. Osteoporosis International, 2013, Vol. 24, pp. 2191-2199 (DOI: 10.1007/s00198-013-2268-y)

10. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis. Arthritis Rheum 58: 1674-1686

11. Larsson S. Anti-sclerostin - is there an indication? Injury. 2016;47(1):31-35. doi: 10.1016/S0020-1383(16)30008-0

12. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.